Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women

Abstract

Selective oestrogen receptor modulators (raloxifene) and statins (atorvastatin) have been shown to reduce the risk of cardiovascular disease associated with the postmenopausal status. Their beneficial effects may be mediated partly by favourable changes in serum lipids and particular on HDL phospholipid composition. In the present study, individual administration of either raloxifene (Group A) or atorvastatin (Group B) or both (Group C) was compared for a period of 3 months and their effects on total lipids and HDL phospholipids were evaluated. The combined treatment of raloxifene and atorvastatin resulted in profound changes in the majority of serum lipids, including a significant reduction in total cholesterol and triglycerides (P < 0.001), a rise in total phospholipids (P < 0.01) and a reduction in LDL-C and Apo B levels (P < 0.001). Furthermore, Apo A-I was elevated (P < 0.001) whereas total HDL phospholipids were significantly increased (P < 0.05). Specifically, HDL phosphatidylcholine levels were markedly increased (P < 0.001) and HDL lysophosphatidylcholine, sphingomyelin and phosphatidylinositol levels were reduced (P < 0.05). A further attempt to evaluate each treatment group was performed and the significance of these results is discussed.